The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized, open-label, phase II study comparing five-weekly S-1 plus cisplatin (SP) with tri-weekly capecitabine plus cisplatin (XP) in chemotherapy-naïve patients with HER2 negative advanced gastric cancer (AGC): OGSG 1105 HERBIS-4A trial.
 
Atsushi Takeno
No Relationships to Disclose
 
Youichi Makari
No Relationships to Disclose
 
Shunji Endo
No Relationships to Disclose
 
Jin Matsuyama
No Relationships to Disclose
 
Ryohei Kawabata
No Relationships to Disclose
 
Naotoshi Sugimoto
No Relationships to Disclose
 
Hirokazu Taniguchi
No Relationships to Disclose
 
Kenichi Nagai
No Relationships to Disclose
 
Shigeyuki Tamura
No Relationships to Disclose
 
Junichi Nishijima
No Relationships to Disclose
 
Shugo Ueda
No Relationships to Disclose
 
Yutaka Kimura
No Relationships to Disclose
 
Takao Tamura
No Relationships to Disclose
 
Kenji Kobayashi
No Relationships to Disclose
 
HIsato Kawakami
No Relationships to Disclose
 
Kazumasa Fujitani
No Relationships to Disclose
 
Daisuke Sakai
Research Funding - Chugai Pharma (Inst); Ono Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Toshio Shimokawa
No Relationships to Disclose
 
Yukinori Kurokawa
Honoraria - Chugai Pharma; Lilly Japan; Novartis; Taiho Pharmaceutical; Yakult Honsha
 
Taroh Satoh
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck Serono; Takeda; Yakult Honsha
Consulting or Advisory Role - Bayer Yakuhin; Lilly; Merck Serono; Ono Pharmaceutical; Takara Bio
Research Funding - Chugai Pharma (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Yakult Honsha (Inst)